
Angelica Corral Garcia Heras

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/698/publications.pdf Version: 2024-02-01



ANGELICA CORRAL GARCIA

#	Article	IF	CITATIONS
1	Plasma Levels of Atazanavir and the Risk of Hyperbilirubinemia Are Predicted by the 3435C->T Polymorphism at the Multidrug Resistance Gene 1. Clinical Infectious Diseases, 2006, 42, 291-295.	2.9	116
2	High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. Aids, 2007, 21, 2503-2511.	1.0	66
3	Correlation between Human Immunodeficiency Virus Type 1 (HIV-1) RNA Measurements Obtained with Dried Blood Spots and Those Obtained with Plasma by Use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV Load Tests. Journal of Clinical Microbiology, 2009, 47, 1031-1036.	1.8	66
4	Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. Journal of Antimicrobial Chemotherapy, 2007, 60, 885-888.	1.3	54
5	Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors and Prevalence of HIV Type 1 Non-B Subtypes Are Increasing among Persons with Recent Infection in Spain. Clinical Infectious Diseases, 2005, 41, 1350-1354.	2.9	53
6	Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. Aids, 2005, 19, 2036-2038.	1.0	46
7	Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. Journal of Medical Virology, 2007, 79, 1040-1046.	2.5	43
8	Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. Aids, 2008, 22, 611-616.	1.0	37
9	Predictors of selection of K65R. Aids, 2004, 18, 2094-2096.	1.0	36
10	Changing Rates and Patterns of Drug Resistance Mutations in Antiretroviral-Experienced HIV-Infected Patients. AIDS Research and Human Retroviruses, 2007, 23, 879-885.	0.5	35
11	High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor. Aids, 2010, 24, 467-469.	1.0	34
12	Changes in the Human Immunodeficiency Virus p7-p1-p6 gag Gene in Drug-Naive and Pretreated Patients. Journal of Clinical Microbiology, 2003, 41, 1245-1247.	1.8	33
13	Preparation and Characterization of Antimicrobial Films Based on LDPE/Ag Nanoparticles with Potential Uses in Food and Health Industries. Nanomaterials, 2018, 8, 60.	1.9	33
14	Evidence for Differences in the Sexual Transmission Efficiency of HIV Strains with Distinct Drug Resistance Genotypes. Clinical Infectious Diseases, 2004, 39, 1231-1238.	2.9	32
15	Antiretroviral Recommendations May Influence the Rate of Transmission of Drugâ€Resistant HIV Type 1. Clinical Infectious Diseases, 2005, 41, 227-232.	2.9	31
16	Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. Journal of Antimicrobial Chemotherapy, 2007, 60, 1409-1410.	1.3	31
17	Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. Aids, 2006, 20, 1071-1074.	1.0	29
18	Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. Aids, 2002, 16, 1830-1832.	1.0	26

ANGELICA CORRAL GARCIA

#	Article	IF	CITATIONS
19	Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. Journal of Virological Methods, 2004, 121, 115-118.	1.0	25
20	Short Communication:Prevalence of G333D/E in Naive and Pretreated HIV-Infected Patients. AIDS Research and Human Retroviruses, 2002, 18, 857-860.	0.5	19
21	Changing Patterns in HIV Reverse Transcriptase Resistance Mutations after Availability of Tenofovir. Clinical Infectious Diseases, 2008, 46, 1782-1785.	2.9	19
22	Short Communication High Risk of Endothelial Dysfunction in HIV Individuals May Result from Deregulation of Circulating Endothelial Cells and Endothelial Progenitor Cells. AIDS Research and Human Retroviruses, 2012, 28, 656-659.	0.5	17
23	Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations. Aids, 2004, 18, 2091-2094.	1.0	16
24	Changes in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in Spain. AIDS Research and Human Retroviruses, 2009, 25, 967-972.	0.5	14
25	Indinavir Plasma Concentrations and Resistance Mutations in Patients Experiencing Early Virological Failure. AIDS Research and Human Retroviruses, 2003, 19, 457-459.	0.5	13
26	Fibrous nanocomposites based on EVA40 filled with Cu nanoparticles and their potential antibacterial action. Materials Today Communications, 2019, 20, 100581.	0.9	13
27	Photoswitching-Enabled Contrast Enhancement in Light Sheet Fluorescence Microscopy. ACS Photonics, 2017, 4, 424-428.	3.2	12
28	PCL/collagen blends prepared by solution blow spinning as potential materials for skin regeneration. Journal of Applied Polymer Science, 2021, 138, 50493.	1.3	10
29	Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance. Journal of Clinical Virology, 2011, 50, 148-152.	1.6	9
30	Prevalence of Novel Lamivudine-Resistant Genotypes (E44D/A, V118I) in Naive and Pretreated HIV-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 95-96.	0.9	8
31	Relationship between drug resistance mutations, plasma viremia, and CD4+T-cell counts in patients with chronic HIV infection. Journal of Medical Virology, 2005, 76, 1-6.	2.5	8
32	Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance. Aids, 2008, 22, 311-313.	1.0	8
33	Use of Different Inhibitory Quotients To Predict Early Virological Response to Tipranavir in Antiretroviral-Experienced Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy, 2009, 53, 4153-4158.	1.4	6
34	Estimated Extent of Cross-Resistance to Ritonavir-Boosted Protease Inhibitors Among Protease Inhibitors-Experienced Patients: Implications for Tipranavir Use. AIDS Patient Care and STDs, 2005, 19, 67-69.	1.1	5
35	Prevalence of the HIV Protease Mutation N88S Causing Hypersensitivity to Amprenavir. Clinical Infectious Diseases, 2002, 34, 1288-1289.	2.9	4
36	Prevalence of drug resistance genotypes causing broad cross-resistance to nucleos(t)ide analogues. Aids, 2004, 18, 689-690.	1.0	4

#	Article	IF	CITATIONS
37	Low rate of HIV-1 codon 215 revertants in antiretroviral-experienced patients. Aids, 2003, 17, 919-921.	1.0	4